<DOC>
<DOCNO>EP-0649426</DOCNO> 
<TEXT>
<INVENTION-TITLE>
INHIBITORS OF RETROVIRAL PROTEASES
</INVENTION-TITLE>
<CLASSIFICATIONS>C07K500	A61K3800	C07K506	A61K3800	C07F932	C07F900	C07F948	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07K	A61K	C07K	A61K	C07F	C07F	C07F	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07K5	A61K38	C07K5	A61K38	C07F9	C07F9	C07F9	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The invention concerns compounds of formula (I), in which Q is an entity of formula (IIa) or (IIb); Y is oxygen or sulphur; and A, R2, R3, R4, R5, R6 and R7 and the corresponding asterisked groups are as defined in the description. The invention also concerns a method of preparing such compounds and the use of the compounds to inhibit retroviral proteases.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
AVENTIS PHARMA GMBH
</APPLICANT-NAME>
<APPLICANT-NAME>
AVENTIS PHARMA DEUTSCHLAND GMBH
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
BUDT KARL-HEINZ
</INVENTOR-NAME>
<INVENTOR-NAME>
LI JIAN-QI
</INVENTOR-NAME>
<INVENTOR-NAME>
PEYMAN ANUSCHIRWAN
</INVENTOR-NAME>
<INVENTOR-NAME>
STOWASSER BERND
</INVENTOR-NAME>
<INVENTOR-NAME>
BUDT, KARL-HEINZ
</INVENTOR-NAME>
<INVENTOR-NAME>
LI, JIAN-QI
</INVENTOR-NAME>
<INVENTOR-NAME>
PEYMAN, ANUSCHIRWAN
</INVENTOR-NAME>
<INVENTOR-NAME>
STOWASSER, BERND
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
A compound of the formula I


in which

Q
is a radical of the formula IIa

Y
is oxygen, 
A
is a radical of the formula IV

D - (E)n -

where

E
is Val, Phe, Ile or Asp, and
n
is 0 or 1;
D
is R
1
 or a radical of the formulae V or VI
R
1
is hydrogen, (C
1
-C
6
)-alkylsulfonyl, phenyl-(C
1
-C
2
)-alkyl,
triphenylmethyl, (C
1
-C
6
)-alkoxycarbonyl or
phenyl-(C
1
-C
2
)-alkoxycarbonyl,
R
2
is hydrogen, phenyl, benzyl, methyl, ethyl,
isopropyl, n-propyl, n-butyl, isobutyl, sec-butyl,

pentyl or cyclohexylmethyl,
R
3
, R
4
, R
8
, R
10
 and R
11
are hydrogen,
R
5
is hydrogen or (C
1
-C
4
)-alkyl,
R
6
is oxygen, and
R
9
is hydrogen, isopropyl, sec-butyl, benzyl, carboxymethyl,
1-naphthylmethyl, 2-(methylthio)ethyl or

indol-2-ylmethyl,

and the physiologically tolerated salts thereof.
A process for preparing a compound of the formula I
as claimed in claim 1, wherein a fragment having a

terminal carboxyl group, or a reactive derivative of
this fragment, is coupled to a corresponding fragment

having a free amino group, (a) protective group(s) which
has/have, where appropriate, been temporarily introduced

to protect further functional groups is/are eliminated,
and the compound thus obtained is, where appropriate,

converted into its physiologically tolerated salt. 
A compound of the formula I as claimed in claim 1 for
use as a medicine.
A compound of the formula I as claimed in claim 1 for
use as an inhibitor of retroviral proteases.
The use of a compound of the formula I as claimed in
claim 1 for preparing pharmaceutical compositions for

the treatment of "acquired immune deficiency syndrome".
A pharmaceutical composition containing a compound
as claimed in claim 1.
</CLAIMS>
</TEXT>
</DOC>
